US2013096173A1PendingUtilityA1

Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence

56
Individually held — no corporate assignee on recordPriority: Sep 9, 2011Filed: Sep 7, 2012Published: Apr 18, 2013
Est. expirySep 9, 2031(~5.1 yrs left)· nominal 20-yr term from priority
Inventors:Bankole A. Johnson
A61P 25/30A61K 31/4178C12Q 2600/106C12Q 1/6883C12Q 2600/156
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides compositions and methods useful for diagnosing, treating, and monitoring alcohol dependence and disorders and susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating an addictive disease or disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of an antagonist of the serotonin receptor 5-HT 3 , wherein the patient's serotonin transporter gene SLC6A4 is known to have a genotype selected from sets (a)-(q):
 (a.) the AA genotype of rs1176719 and the AG genotype of rs1150226;   (b.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942;   (c.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (d.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (e.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (f.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (g.) the AA genotype of rs1176719 and the GG genotype of rs1176713;   (h.) the AA genotype of rs1176719 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (i.) the AA genotype of rs1176719 and the GG genotype of rs1176713 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (j.) the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (k.) the GG genotype of rs1176713 and the AG genotype of rs1150226 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (l.) the GG genotype of rs1176713 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (m.) the GG genotype of rs1176713 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;   (n.) the AG genotype of rs1150226 and the AA genotype of rs1176719 and the AC genotype of rs17614942 and the GG genotype of rs1176713;   (o.) the AG genotype of rs1150226 and the AA genotype of rs1176719 and the GG genotype of rs1176713;   (p.) the AG genotype of rs1150226 and the AC genotype of rs17614942 and the GG genotype of rs1176713; and,   (q.) the AA genotype of rs1176719 and the AC genotype of rs17614942 and the GG genotype of rs1176713.   
     
     
         2 . The method of  claim 1 , wherein the patient is known to have genotype set (a). 
     
     
         3 . The method of  claim 1 , wherein the patient is known to have genotype set (b). 
     
     
         4 . The method of  claim 1 , wherein the patient is known to have genotype set (c). 
     
     
         5 . The method of  claim 1 , wherein the patient is known to have genotype set (d). 
     
     
         6 . The method of  claim 1 , wherein the patient is known to have genotype set (e). 
     
     
         7 . The method of  claim 1 , wherein the patient is known to have genotype set (f). 
     
     
         8 . The method of  claim 1 , wherein the patient is known to have genotype set (g). 
     
     
         9 . The method of  claim 1 , wherein the patient is known to have genotype set (h). 
     
     
         10 . The method of  claim 1 , wherein the patient is known to have genotype set (i). 
     
     
         11 . The method of  claim 1 , wherein the patient is known to have genotype set (j). 
     
     
         12 . The method of  claim 1 , wherein the patient is known to have genotype set (k). 
     
     
         13 . The method of  claim 1 , wherein the patient is known to have genotype set (l). 
     
     
         14 . The method of  claim 1 , wherein the patient is known to have genotype set (m). 
     
     
         15 . The method of  claim 1 , wherein the patient is known to have genotype set (n). 
     
     
         16 . The method of  claim 1 , wherein the patient is known to have genotype set (O). 
     
     
         17 . The method of  claim 1 , wherein the patient is known to have genotype set (p). 
     
     
         18 . The method of  claim 1 , wherein the patient is known to have genotype set (q). 
     
     
         19 . The method of  claim 1 , wherein the antagonist of the serotonin receptor 5-HT 3  is administered at a dosage ranging from 0.1 μg/kg to 1000 μg/kg per application. 
     
     
         20 . The method of  claim 19 , wherein the antagonist of the serotonin receptor 5-HT 3  is ondansetron. 
     
     
         21 . The method of  claim 20 , wherein the ondanesetron is administered at a dosage of 3.0 μg/kg per application. 
     
     
         22 . The method of  claim 20 , wherein the ondanesetron is administered at a dosage of 4.0 μg/kg per application. 
     
     
         23 . The method of  claim 1 , wherein the addictive disease or disorder is selected from the group consisting of alcohol-related diseases and disorders, obesity-related diseases and disorders, eating disorders, impulse control disorders, nicotine-related disorders, amphetamine-related disorders, methamphetamine-related disorders, cannabis-related disorders, cocaine-related disorders, hallucinogen use disorders, inhalant-related disorders, benzodiazepine abuse or dependence related disorders, opioid-related disorders, gambling, sexual disorders, computer use related disorders, and electronic use related disorders. 
     
     
         24 . The method of  claim 23 , wherein the addictive disease or disorder is an alcohol-related disease or disorder. 
     
     
         25 . The method of  claim 24 , wherein the alcohol-related disease or disorder is selected from the group consisting of early onset alcoholism, late onset alcoholism, alcohol-induced psychotic disorder with delusions, alcohol abuse, heavy drinking, excessive drinking, alcohol intoxication, alcohol withdrawal, alcohol intoxication delirium, alcohol withdrawal delirium, alcohol-induced persisting dementia, alcohol-induced persisting amnestic disorder, alcohol dependence, alcohol-induced psychotic disorder with hallucinations, alcohol-induced mood disorder, alcohol-induced or associated bipolar disorder, alcohol-induced or associated post traumatic stress disorder, alcohol-induced anxiety disorder, alcohol-induced sexual dysfunction, alcohol-induced sleep disorder, alcohol-induced or associated gambling disorder, alcohol-induced or associated sexual disorder, alcohol-related disorder not otherwise specified, alcohol intoxication, and alcohol withdrawal. 
     
     
         26 . The method of  claim 1 , wherein a response from the treatment, comprises: a reduction in drinking. 
     
     
         27 . A method of selecting patients with an addictive disease or disorder who will be responsive to treatment with an antagonist of the serotonin receptor 5-HT 3 , comprising:
 determining whether the patient's serotonin transporter gene SLC6A4 has a genotype set selected from sets (a)-(q):
 (a.) the AA genotype of rs1176719 and the AG genotype of rs1150226; 
 (b.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942; 
 (c.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; 
 (d.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; 
 (e.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; 
 (f.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; 
 (g.) the AA genotype of rs1176719 and the GG genotype of rs1176713; 
 (h.) the AA genotype of rs1176719 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; 
 (i.) the AA genotype of rs1176719 and the GG genotype of rs1176713 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; 
 (j.) the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; 
 (k.) the GG genotype of rs1176713 and the AG genotype of rs1150226 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; 
 (l.) the GG genotype of rs1176713 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; 
 (m.) the GG genotype of rs1176713 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; 
 (n.) the AG genotype of rs1150226 and the AA genotype of rs1176719 and the AC genotype of rs17614942 and the GG genotype of rs1176713; 
 (o.) the AG genotype of rs1150226 and the AA genotype of rs1176719 and the GG genotype of rs1176713; 
 (p.) the AG genotype of rs1150226 and the AC genotype of rs17614942 and the GG genotype of rs1176713; and, 
 (q.) the AA genotype of rs1176719 and the AC genotype of rs17614942 and the GG genotype of rs1176713. 
   
     
     
         28 . The method of  claim 17 , further comprising:
 administering an antagonist of the serotonin receptor 5-HT 3  to the patient, if the patient has a genotype of set (a)-(q).

Join the waitlist — get patent alerts

Track US2013096173A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.